Tags

Type your tag names separated by a space and hit enter

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
J Hepatol. 2004 Mar; 40(3):484-90.JH

Abstract

BACKGROUND/AIMS

Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes.

METHODS

We evaluated liver biopsies from 574 patients with chronic hepatitis C from a single center.

RESULTS

Severity of steatosis was associated with body mass index, HCV genotype 3 infection, age, and duration of infection (P</=0.01). Serum HCV RNA levels were associated with severity of steatosis in HCV genotype 3 infection (P</=0.03). In HCV genotype 1 infection, fibrosis was associated with severity of steatosis (P<0.01), and patients who achieved SVR had lesser degrees of pre-treatment steatosis compared to nonresponders (4.6+/-1.6 vs. 10.1+/-1.1%, P=0.02). Genotype 1 infected patients with an early virologic response were more likely to have grade 0 steatosis compared to those without an early response (71 vs. 42%; P=0.003). Evaluation of paired biopsies demonstrated a marked decline in steatosis in genotype 3 patients who achieved SVR (P<0.01).

CONCLUSIONS

In conclusion, steatosis is an important cofactor in hepatitis C as it is associated with fibrosis and reduces the likelihood of achieving early and sustained virologic response in genotype 1 infected patients.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15123364

Citation

Patton, Heather M., et al. "The Impact of Steatosis On Disease Progression and Early and Sustained Treatment Response in Chronic Hepatitis C Patients." Journal of Hepatology, vol. 40, no. 3, 2004, pp. 484-90.
Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40(3):484-90.
Patton, H. M., Patel, K., Behling, C., Bylund, D., Blatt, L. M., Vallée, M., Heaton, S., Conrad, A., Pockros, P. J., & McHutchison, J. G. (2004). The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. Journal of Hepatology, 40(3), 484-90.
Patton HM, et al. The Impact of Steatosis On Disease Progression and Early and Sustained Treatment Response in Chronic Hepatitis C Patients. J Hepatol. 2004;40(3):484-90. PubMed PMID: 15123364.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. AU - Patton,Heather M, AU - Patel,Keyur, AU - Behling,Cynthia, AU - Bylund,David, AU - Blatt,Lawrence M, AU - Vallée,Marc, AU - Heaton,Shanon, AU - Conrad,Andrew, AU - Pockros,Paul J, AU - McHutchison,John G, PY - 2003/04/15/received PY - 2003/10/22/revised PY - 2003/11/03/accepted PY - 2004/5/5/pubmed PY - 2004/11/13/medline PY - 2004/5/5/entrez SP - 484 EP - 90 JF - Journal of hepatology JO - J Hepatol VL - 40 IS - 3 N2 - BACKGROUND/AIMS: Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes. METHODS: We evaluated liver biopsies from 574 patients with chronic hepatitis C from a single center. RESULTS: Severity of steatosis was associated with body mass index, HCV genotype 3 infection, age, and duration of infection (P</=0.01). Serum HCV RNA levels were associated with severity of steatosis in HCV genotype 3 infection (P</=0.03). In HCV genotype 1 infection, fibrosis was associated with severity of steatosis (P<0.01), and patients who achieved SVR had lesser degrees of pre-treatment steatosis compared to nonresponders (4.6+/-1.6 vs. 10.1+/-1.1%, P=0.02). Genotype 1 infected patients with an early virologic response were more likely to have grade 0 steatosis compared to those without an early response (71 vs. 42%; P=0.003). Evaluation of paired biopsies demonstrated a marked decline in steatosis in genotype 3 patients who achieved SVR (P<0.01). CONCLUSIONS: In conclusion, steatosis is an important cofactor in hepatitis C as it is associated with fibrosis and reduces the likelihood of achieving early and sustained virologic response in genotype 1 infected patients. SN - 0168-8278 UR - https://www.unboundmedicine.com/medline/citation/15123364/The_impact_of_steatosis_on_disease_progression_and_early_and_sustained_treatment_response_in_chronic_hepatitis_C_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168827803005828 DB - PRIME DP - Unbound Medicine ER -